ArticleJournal of thoracic disease2026
Impact of perioperative chemotherapy on survival outcomes in patients with non-small cell lung cancer undergoing pneumonectomy: a SEER database analysis.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pneumonectomy for locally advanced non-small cell lung cancer (NSCLC) carries significant risk. While perioperative chemotherapy is standard for multimodality treatment, its specific impact on long-term survival in this high-risk surgical cohort is not well-defined. This study aims to evaluate the impact of chemotherapy on long-term survival in patients with locally advanced NSCLC undergoing pneumonectomy. Methods: Data from 640 patients with T3-4N0-3M0 NSCLC who underwent pneumonectomy were extracted from the Surveillance, Epidemiology, and End Results (SEER) database (2007-2021). Patients were grouped by chemotherapy receipt and analyzed for the timing of chemotherapy. Propensity score matching (PSM) was applied to balance baseline differences. Survival outcomes were analyzed using Cox regression and subgroup interaction analyses. Results: A total of 640 patients met the inclusion criteria, of whom 390 (60.9%) received chemotherapy. The chemotherapy group was younger, had more advanced nodal disease, and higher radiotherapy rates (all P<0.001). After PSM, 204 patients were included in each group. Compared with surgery alone, chemotherapy was associated with significantly longer overall survival (OS) (median OS: 67.0 Conclusions: Chemotherapy is associated with improved survival in locally advanced NSCLC after pneumonectomy. Neoadjuvant and adjuvant chemotherapy show comparable efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.